{"id":"W2906546777","doi":"10.1016/j.jval.2018.09.718","title":"PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Empagliflozin; Semaglutide; Lixisenatide; Liraglutide; Medicine; Dulaglutide; Exenatide; Internal medicine; Glucagon-like peptide 1 receptor; Type 2 diabetes; Hazard ratio; Myocardial infarction; Diabetes mellitus; Cardiology; Pharmacology; Endocrinology; Confidence interval; Agonist; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001465542,0.0002478233,0.001659155,0.0002076885,0.00008892044,0.0000209033,0.0001106925,0.00008402213,0.00003367697],"category_scores_gemma":[0.0001974827,0.0001963767,0.0002310568,0.0006211911,0.0001036716,0.00007724095,0.0000719425,0.0001860914,0.00004083206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003182563,"about_ca_system_score_gemma":0.0001476391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002820442,"about_ca_topic_score_gemma":0.00002752658,"domain_scores_codex":[0.9975117,0.0004813178,0.0008521731,0.0003857158,0.000384326,0.0003847783],"domain_scores_gemma":[0.9985542,0.0001564746,0.0002683253,0.0007020734,0.0001134272,0.0002055559],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0006916376,0.0008267109,0.007490894,0.9174682,0.004861564,0.00006053798,0.003824444,0.00003645056,0.00001857492,0.001363036,0.05807961,0.005278306],"study_design_scores_gemma":[0.01665163,0.006551019,0.01571155,0.6731972,0.006825296,0.00006053112,0.001136041,0.0007319847,0.0002032086,0.00004458578,0.2779379,0.0009490771],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04239016,0.9441875,0.00005247101,0.002614033,0.001137871,0.00616116,0.00006650629,0.0001090671,0.003281228],"genre_scores_gemma":[0.3484764,0.6354666,0.009245972,0.00322011,0.0005288245,0.0004542716,0.0004259913,0.0001281355,0.002053688],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3087209,"threshold_uncertainty_score":0.8008009,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03565310845774038,"score_gpt":0.2958013506025581,"score_spread":0.2601482421448177,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}